从实验室到临床：临床开发中的 PI3K 通路抑制剂。
From the bench to the bed side: PI3K pathway inhibitors in clinical development.
机构信息
Oncology Drug Discovery, Novartis Institutes for Biomedical Research, Vitry-sur-Seine Cedex, France.
出版信息
Curr Top Microbiol Immunol. 2010;347:209-39. doi: 10.1007/82_2010_60.
PMID:20582534
Abstract
A number of intracellular kinase components of the PI3K/Akt/mTOR pathway have been targeted over the past few years, leading to a new generation of anticancer agents that effectively and specifically disrupt this pathway in tumor cells. Here, progress in the identification and clinical evaluation of compounds designed to modulate the enzymatic activity of PI3K, Akt, mTOR, and Hsp90 is reviewed.
摘要
近年来，已经有许多 PI3K/Akt/mTOR 通路的细胞内激酶成分成为了靶向治疗的目标，由此产生了新一代的抗癌药物，这些药物能够有效地、特异性地破坏肿瘤细胞中的这条通路。在此，我们回顾了用于调节 PI3K、Akt、mTOR 和 Hsp90 的酶活性的化合物的鉴定和临床评估方面的进展。
Zotero 插件